(4-Amino-2-methylpyrimidin-5-yl)methylcarbamic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: (4-Amino-2-methylpyrimidin-5-yl)methylcarbamic acid
• 英文别名: (4-amino-2-methylpyrimidin-5-yl)methylcarbamic acid
• 化学式: C₇H₁₀N₄O₂
• 分子量: 182.18
• InChiKey: JGNZNBGIMDVHLY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  101
• 氢给体数：
  3
• 氢受体数：
  5

文献信息

• METHODS OF LOWERING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9)
  申请人：Catabasis Pharmaceuticals, Inc.

  公开号：EP2854787A2

  公开（公告）日：2015-04-08
• [EN] METHODS OF LOWERING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9)<br/>[FR] MÉTHODES DE DIMINUTION DE LA PROPROTÉINE CONVERTASE SUBTILISINE/KEXINE DE TYPE 9 (PCSK9)
  申请人：CATABASIS PHARMACEUTICALS INC

  公开号：WO2013177536A2

  公开（公告）日：2013-11-28

  The invention relates to new methods of modulating cholesterol by inhibiting proprotein convertase subtilisin/kexin type 9 (PCSK9) with fatty acid derivatives; and new methods for treating or preventing a metabolic disease comprising the administration of an effective amount of a fatty acid derivative. The present invention is also directed to fatty acid bioative derivatives and their use in the treatment of metabolic diseases.